Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

553 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effectiveness and safety of dolutegravir two-drug regimens in virologically suppressed people living with HIV: a systematic literature review and meta-analysis of real-world evidence.
Punekar YS, Parks D, Joshi M, Kaur S, Evitt L, Chounta V, Radford M, Jha D, Ferrante S, Sharma S, Van Wyk J, de Ruiter A. Punekar YS, et al. Among authors: van wyk j. HIV Med. 2021 Jul;22(6):423-433. doi: 10.1111/hiv.13050. Epub 2021 Feb 2. HIV Med. 2021. PMID: 33529489 Free PMC article.
Using Climate-HIV to describe real-world clinical outcomes for people living with HIV taking dolutegravir-based regimens.
Okoli C, Schwenk A, Radford M, Myland M, Taylor S, Barnes J, Fox A, Darley A, Grimson F, Reeves I, Munshi S, Croucher A, Boxall N, Paice A, van Wyk J, Benn P. Okoli C, et al. Among authors: van wyk j. Int J STD AIDS. 2021 Oct;32(12):1165-1173. doi: 10.1177/09564624211027099. Epub 2021 Jun 22. Int J STD AIDS. 2021. PMID: 34156330 Free PMC article.
Dolutegravir-based regimens in treatment-naive and treatment-experienced aging populations: analyses of 6 phase III clinical trials.
Spinelli F, Prakash M, Slater J, van der Kolk M, Bassani N, Grove R, Wynne B, van Wyk J, Clark A. Spinelli F, et al. Among authors: van der kolk m, van wyk j. HIV Res Clin Pract. 2021 Apr;22(2):46-54. doi: 10.1080/25787489.2021.1941672. Epub 2021 Jun 28. HIV Res Clin Pract. 2021. PMID: 34180785 Free article. Clinical Trial.
Why START? Reflections that led to the conduct of this large long-term strategic HIV trial.
INSIGHT Strategic Timing of AntiRetroviral Treatment (START) Study Group; Lundgren J, Babiker A, Gordin F, Emery S, Fätkenheuer G, Molina JM, Wood R, Neaton JD. INSIGHT Strategic Timing of AntiRetroviral Treatment (START) Study Group, et al. HIV Med. 2015 Apr;16 Suppl 1(0 1):1-9. doi: 10.1111/hiv.12227. HIV Med. 2015. PMID: 25711317 Free PMC article. No abstract available.
Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial.
Paton NI, Kityo C, Thompson J, Nankya I, Bagenda L, Hoppe A, Hakim J, Kambugu A, van Oosterhout JJ, Kiconco M, Bertagnolio S, Easterbrook PJ, Mugyenyi P, Walker AS; Europe Africa Research Network for Evaluation of Second-line Therapy (EARNEST) Trial Team. Paton NI, et al. Lancet HIV. 2017 Aug;4(8):e341-e348. doi: 10.1016/S2352-3018(17)30065-6. Epub 2017 May 8. Lancet HIV. 2017. PMID: 28495562 Free PMC article. Clinical Trial.
553 results